Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.

Fritzinger DC, Hew BE, Thorne M, Pangburn MK, Janssen BJ, Gros P, Vogel CW.

Dev Comp Immunol. 2009;33(1):105-16. doi: 10.1016/j.dci.2008.07.006.

PMID:
18760301
2.

Recombinant cobra venom factor.

Vogel CW, Fritzinger DC, Hew BE, Thorne M, Bammert H.

Mol Immunol. 2004 Jun;41(2-3):191-9. Review.

PMID:
15159065
3.

Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion.

Vogel CW, Fritzinger DC.

Toxicon. 2010 Dec 15;56(7):1198-222. doi: 10.1016/j.toxicon.2010.04.007. Review.

PMID:
20417224
4.
5.

Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.

Fritzinger DC, Hew BE, Lee JQ, Newhouse J, Alam M, Ciallella JR, Bowers M, Gorsuch WB, Guikema BJ, Stahl GL, Vogel CW.

Adv Exp Med Biol. 2008;632:293-307. Review.

PMID:
19025130
6.

Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models.

Vogel CW, Finnegan PW, Fritzinger DC.

Mol Immunol. 2014 Oct;61(2):191-203. doi: 10.1016/j.molimm.2014.06.035. Review.

PMID:
25062833
7.

Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.

Vogel CW, Fritzinger DC, Gorsuch WB, Stahl GL.

Thromb Haemost. 2015 Mar;113(3):548-52. doi: 10.1160/TH14-04-0300. Review.

PMID:
25031089
8.

The cobra complement system: I. The alternative pathway of activation.

Vogel CW, Müller-Eberhard HJ.

Dev Comp Immunol. 1985 Spring;9(2):311-25. Review.

PMID:
3894085
9.

Structure/function of C5 convertases of complement.

Rawal N, Pangburn MK.

Int Immunopharmacol. 2001 Mar;1(3):415-22. Review.

PMID:
11367526
Items per page

Supplemental Content

Support Center